GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. “Inclusion in the Russell 3000® Index is an important milestone in Emergent’s ongoing transformation,” said Joe Papa, president and chief executive officer of Emergent BioSolutions. “This recognition reflects ...

Core Insights - Emergent BioSolutions Inc. announced participation in several upcoming investor conferences, indicating active engagement with the investment community [1][3]. Company Overview - Emergent BioSolutions has a mission to protect and save lives, focusing on delivering solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [2]. Upcoming Events - The company will participate in the RBC Global Healthcare Conference on May 20, 2025, with a fireside chat scheduled for 3:35 pm ET, available for virtual attendees via webcast [3]. - Emergent will also present at the Goldman Sachs Leveraged Finance Conference on May 29, 2025, in Dana Point, California [3]. - Additionally, the company is set to present at Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference on May 29, 2025 [3]. - The Jefferies Global Healthcare Conference presentation is scheduled for June 5, 2025, at 1:25 pm ET, also available for virtual participation [3].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Bavarian Nordic A/S has received an additional contract option from BARDA valued at USD 143.6 million for the supply of freeze-dried JYNNEOS smallpox vaccine [1][10] - The new contract options will support the manufacturing and supply of the freeze-dried formulation, which has an extended shelf life, with deliveries planned for 2026 [2][8] Financial Guidance - Bavarian Nordic's financial guidance for 2025 remains unchanged, projecting total revenues between DKK 5,700 million and DKK 6,700 million, with an EBITDA margin of 26-30% [3] - Revenue from the Public Preparedness business is expected to be between DKK 3,000 million and DKK 4,000 million, with DKK 2,650 million already secured, reflecting an increase of DKK 150 million due to the exercise of the options [3] Product Development and Approval - The freeze-dried formulation of JYNNEOS was approved by the FDA in March 2025, offering advantages in transportation, storage, and shelf life compared to the liquid-frozen version [8] - JYNNEOS is the first smallpox vaccine developed under Project BioShield, which aims to enhance the availability of medical countermeasures against various threats [6] Historical Context - Bavarian Nordic has been collaborating with the U.S. government since 2003 for the development and supply of smallpox vaccines, including the liquid-frozen formulation supplied since 2010 [5][7] - The company has a ten-year contract awarded in 2017, which includes options valued at USD 299 million for the fill and finish of freeze-dried vaccines, of which USD 284 million has been exercised to date [7]